TITLE

Hypocretin (orexin) cell loss in Parkinsons disease

AUTHOR(S)
Thomas C. Thannickal; Yuan-Yang Lai; Jerome M. Siegel
PUB. DATE
June 2007
SOURCE
Brain: A Journal of Neurology;Jun2007, Vol. 130 Issue 6, p1586
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
It has recently been reported that Parkinsons disease (PD) is preceded and accompanied by daytime sleep attacks, nocturnal insomnia, REM sleep behaviour disorder, hallucinations and depression, symptoms which are frequently as troublesome as the motor symptoms of PD. All these symptoms are present in narcolepsy, which is linked to a selective loss of hypocretin (Hcrt) neurons. In this study, the Hcrt system was examined to determine if Hcrt cells are damaged in PD. The hypothalamus of 11 PD (mean age 79 ± 4) and 5 normal (mean age 77 ± 3) brains was examined. Sections were immunostained for Hcrt-1, melanin concentrating hormone (MCH) and alpha synuclein and glial fibrillary acidic protein (GFAP). The substantia nigra of 10 PD brains and 7 normal brains were used for a study of neuromelanin pigmented cell loss. The severity of PD was assessed using the Hoehn and Yahr scale and the level of neuropathology was assessed using the Braak staging criteria. Cell number, distribution and size were determined with stereologic techniques on a one in eight series. We found an increasing loss of hypocretin cells with disease progression. Similarly, there was an increased loss of MCH cells with disease severity. Hcrt and MCH cells were lost throughout the anterior to posterior extent of their hypothalamic distributions. The percentage loss of Hcrt cells was minimal in stage I (23%) and was maximal in stage V (62%). Similarly, the percentage loss of MCH cells was lowest in stage I (12%) and was highest in stage V (74%). There was a significant increase (P = 0.0006, t = 4.25, df = 15) in the size of neuromelanin containing cells in PD patients, but no difference in the size of surviving Hcrt (P = 0.18, t = 1.39, df = 14) and MCH (P = 0.28, t = 1.39, df = 14) cells relative to controls. In summary, we found that PD is characterized by a massive loss of Hcrt neurons. Thus, the loss of Hcrt cells may be a cause of the narcolepsy-like symptoms of PD and may be ameliorated by treatments aimed at reversing the Hcrt deficit. We also saw a substantial loss of hypothalamic MCH neurons. The losses of Hcrt and MCH neurons are significantly correlated with the clinical stage of PD, not disease duration, whereas the loss of neuromelanin cells is significantly correlated only with disease duration. The significant correlations that we found between the loss of Hcrt and MCH neurons and the clinical stage of PD, in contrast to the lack of a relationship of similar strength between loss of neuromelanin containing cells and the clinical symptoms of PD, suggests a previously unappreciated relationship between hypothalamic dysfunction and the time course of the overall clinical picture of PD.
ACCESSION #
25208687

 

Related Articles

  • Avicena starts phase III Parkinson's trial.  // PharmaWatch: CNS;May2007, Vol. 6 Issue 5, p5 

    The article reports on the initiation of patient enrollment in a phase III efficacy trial of PD-02, the Avicena Group's Parkinson's disease drug candidate by the National Institute of Neurological Disorders and Strok (NINDS) in the U.S. PD-02 is an ultra-pure form of creatine that is made not to...

  • Some Suggestions and Resources for Individuals With Parkinson's Disease.  // ASHA Leader;7/24/2001, Vol. 6 Issue 13, p7 

    Presents suggestions and resources for individuals with Parkinson's disease. Assistance from a neurologist who has expertise in the disease; Acquisition of medical news and information for patients or friends of patients diagnosed with the disease; Incidence of Young Parkinson's.

  • Untitled.  // New Yorker;10/23/1971, Vol. 47 Issue 36, p175 

    An excerpt from an article on a patient with Parkinson's Disease published in an issue of the "Bath-Brunswick Times-Record" newspaper in 1971 is presented.

  • Not Just A Family Affair. Centofanti, Marjorie // Psychology Today;Jul/Aug99, Vol. 32 Issue 4, p18 

    Reports on the rise in the number of those worried regarding getting Parkinson's Disease (PD), according to a research. Manifestations of the disease; Comments from Doctor Caroline Tanner; Other details of the research.

  • Cognitive and behavioral disturbances in Parkinson's disease. Girotti, F.; Soliveri, P. // Neurological Sciences;May2003 Supplement 1, Vol. 24, ps30 

    The dysfunction of the striato frontal circuits that occurs in Parkinson's disease results in cognitive and behavioural problems as well as motor impairment. Depression is frequent and cognitive deficits also occur that progress with advancing illness, sometimes to subcortical dementia. Spread...

  • Motor complications of Parkinson's disease. Martignoni, E.; Riboldazzi, G.; Calandrella, D.; Riva, N. // Neurological Sciences;May2003 Supplement 1, Vol. 24, ps27 

    Long-term treatment with levodopa in Parkinson's disease results in the development of motor complications, including drug failure, reduced duration of antiparkinsonian action (wearing off phenomenon), sudden shifts between under-treated and over-treated states (on-off phenomenon), freezing and...

  • AT A GLANCE Parkinson's disease.  // GP: General Practitioner;11/11/2002, p67 

    Focuses on Parkinson's disease. Clinical features of the disease; Investigation of the disease; Treatment of Parkinson's disease.

  • Combined PET/MRS brain studies show dynamic and long-term physiological changes in a primate model of Parkinson disease. Brownell, Anna-Liisa; Jenkins, Bruce G.; Elmaleh, David R.; Deacon, Terrence W.; Spealman, Roger D.; Isacson, Ole // Nature Medicine;Nov98, Vol. 4 Issue 11, p1308 

    We used brain imaging to study long-term neurodegenerative and bioadaptive neurochemical changes in a primate model of Parkinson disease. We gradually induced a selective loss of nigrostriatal dopamine neurons, similar to that of Parkinson disease, by creating oxidative stress through infusion...

  • Corrigendum: Advances in non-dopaminergic pharmacological treatments of Parkinson's disease. Stayte, Sandy; Vissel, Bryce // Frontiers in Neuroscience;Aug2014, p1 

    A correction to the article "Advances in non-dopaminergic pharmacological treatments of Parkinson's disease" is presented.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics